Efficacy and Safety of Oral NSAIDS

Yıl 2017, Cilt: 9 Sayı: 2, 69 - 71, 25.03.2017

Dr. Bahar Dernek

Öz

Anahtar Kelimeler

NSAID, Efficacy, Safety, Pain

Oral NSAİİ’lerin Etkinlik ve Güvenlik Açısından Yeri

Öz

Öz

Oral ve Topikal NSAİİ günümüzde klinisyenler tarafından ağrı tedavisinde sıklıkla kullanılmaktadır. Oral NSAİİ kullanımı yan etki olarak gastrointestinal problemlere (peptikülser, gastrointestinal kanama vs.), renal fonksiyon bozukluklarına ve kardiyovasküler problemlere  yol açabilmektedir.  Bu ilaçların sistemik yan etkilerinden dolayı, kullanım öncesi hasta detaylı incelenmeli, komorbid faktörler açısından değerlendirilmelidir.

Anahtar Kelimeler

NSAİİ, Etkinlik, Güvenlik, Ağrı

Kaynakça

• Kaynaklar 1.Roth SH, Anderson S. The NSAID dilemma: managing oste-oarthritis in high-risk patients. Phys Sportsmed. 2011;39:62-74. doi: 10.3810/psm.2011.09.1922. Review. 2.Sneader W. The discovery of aspirin: a reappraisal. BMJ.2000;321(7276): 1591–1594 3.Roth SH. Nonsteroidal anti-inflammatory drugs: gastropathy,deaths, and medical practice. Ann Intern Med.1988;109(5):353–354 4.Roth SH. Understanding the COX-2/NSAID dilemma. Drugs.2005;65(14):1915–1917. 5.Henry D, McGettihan P. Epidemiology overview of gastroin-testinal and renal toxicity of NSAIDs. Int J Clin Pract Suppl2003;135:43-9 6.Garcia Rodriguez LA, Hernandez-Diaz S. The risk of uppergastrointestinal complications associated with nonsteroidalanti-inflammatory drugs, glucocorticoids, acetaminophen, andcombinations of these agents. Arthritis Res 2001;3:98-101 7.Harirforoosh S, Jamali F. Renal adverse effects of nonsteroi-dal antiinflammatory drugs. Expert Opin Drug Saf.2009;8(6):669–681. 8.Harirforoosh S, Jamali F. Renal adverse effects of nonsteroi-dal antiinflammatory drugs. Expert Opin Drug Saf.2009;8(6):669–681. 9.Chaiamnuay S, Allison JJ, Curtis JR. Risks versus benefits ofcyclooxygenase-2-selective nonsteroidal antiinflammatorydrugs. Am J Health Syst Pharm. 2006;63(19):1837–1851. 10.Weir MR, Sperling RS, Reicin A, Gertz BJ. Selective COX-2inhibition and cardiovascular effects: a review of the rofeco-xib development program. Am Heart J. 2003;146(4):591–604. 11.Radford MG, Holley KE, Grande JP, et al. Reversible mem-branous nephropathy associated with the use of nonsteroidalanti-inflammatory drugs. JAMA. 1996;276(6):466–469. 12.Bruyere O, Cooper C, Pelltier JP, Branco J, Brandi ML, Gu-illemin F, et al. An algorithm recommendation fort he mana-gement of knee osteoarthritis in Europe and internationally:a report from a task force of European Society for Clinical andEconomic Aspect of Oteoporosis and Osteoarthritis (ESCEO).Semin Arthritis Rheum 2014;44:253-63 13.National Clinical Guideline Centre. Osteoarthritis care andmanagement in adults: methods, evidence and recommenda-tions. Report No. CG177. London, UK: National Institute forHealth and Care Excellence; February 2014 14.Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R,et al. Patient preference for Placebo, Acetaminophen (para-cetamol) or Celecoxib Efficacy Studies (PACES): two rando-mised, double blind, placebo controlled, crossover clinical tri-als in patients with knee or hip osteoarthritis. Ann Rheum Dis2004; 63:931-9. 15.Chou R, McDonagh MS, Nakamoto E, Griffin J. Analgesicsfor osteoarthritis: an update of the 2006 comparative effec-tiveness review. Rockville, MD: Available from:(http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0016485(pdf/TOC.pdf); October 2011 16.Pelletier JP, Martel-Pelletier J, Rannou F, Cooper C. Efficacyand safety of oral NSAIDs and analgesics in the managementof osteoarthritis: Evidence from real-life setting trials and sur-veys. Semin Arthritis Rheum. 2016;45:S22-7. doi: 10.1016/j.se-marthrit.2015.11.009. 17.FDA. News release: FDA announces series of changes to theclass of marketed non-steroidal anti-inflammatory drugs(NSAIDs). Available from: (http:// www. fda.gov/ NewsEvents/Newsroom/PressAnnouncements/2005/ucm108427.htm) 18.Castellsague J, Tiera-Guardia N, Calingaert B, Varas-Loren-zo C, Fourrier-Reglat A, Nicotra F, et al. Individual NSAIDsand upper gastrointestinal complications : a systematic revi-ew and meta-analysis of observational studies (the SOS Pro-ject). Drug Saf 2012;35:1127-46. 19.Masso Gonzalez EL, Patrignani P, Tacconelli S, Garcia Rod-riquez LA, Variability among nonsteroidal antiinflammatorydrugs in risk of upper gastrointestinal bleeding Arthritis Rhe-um 2010;62:1592-601. 20.Chou CT, Tsai YY. A double-blind, randomized, controlled pa-rallel group study avaluating the efficacy and safety of ace-metacin fort he management of osteoarthritis. Int J Clin PharmRes 2002;12:1-6. 21.Freston JW. Rationalizing cyclooxygenase (COX) inhibitionfor maximal efficacy and minimal adverse events. Am J Med1999;107:78S-88S 22.Lipani JA, Poland M. Clinical update of the relative safety ofnabumetone in long-term clinical trials. Inflammopharmaco-logy 1995;3:351-61. 23.Bhala N, Emberson J, Merhi A, Abramson S, Arber N, BaronJA, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of indivi-dual participant data from randomised trials. Lancet2013;382:769-79. 24.Trelle S, Reichenbach S, Wandel S, Hilderbrand P, Tschan-nen V, Villiger PM, et al. Cardiovascular safety of non-ste-roidal anti-inflammatory drugs: notwork meta-analysis. Br MedJ 2011;342:c7086 25.Singh G, Mithal A, Triadafilopoulos G. Both elective COX-2 inhibitors and non-selective NSAIDs increase the risk of acu-te myocardial infarction in patients with arthritis: selectivityis with the patient, not the drug class, EULAR 2005 June 8-11 Vienna, Austria; 2005.p. OP0091. 26.Pressly TA. The use of nonsteroidal anti-inflammatory me-dications: a therapeutic dilemma. J La State Med Soc.1992;144(12):575–578.